Pharmacodynamics of Moxifloxacin against Anaerobes Studied in an In Vitro Pharmacokinetic Model
Open Access
- 1 October 2005
- journal article
- research article
- Published by American Society for Microbiology in Antimicrobial Agents and Chemotherapy
- Vol. 49 (10) , 4234-4239
- https://doi.org/10.1128/aac.49.10.4234-4239.2005
Abstract
The antibacterial effects of moxifloxacin against Bacteroides fragilis , Clostridium perfringens , and gram-positive anaerobic cocci (GPAC) were studied in an in vitro pharmacokinetic model. Initially, a dose-ranging study with area under the concentration-time curve (AUC)/MIC ratios of 6.7 to 890 was used to investigate the effect of anaerobic conditions on the AUC/MIC antibacterial effect (ABE) relationship with Escherichia coli . The AUC/MIC ratios for 50% and 90% effects, using a log CFU drop at 24 h as the antibacterial effect measure, were 34 and 59, respectively, aerobic and 54 and 96, respectively, anaerobic. These values are not significantly different. Dose ranging at AUC/MIC ratios of 9 to 216 against the anaerobes indicated a differing AUC/MIC ABE pattern, and the AUC/MICs for 50% and 90% effects were lower: for B. fragilis , they were 10.5 and 25.7, respectively; for C. perfringens , they were 8.6 and 16.2; and for GPAC, they were 7.3 and 17.4. The maximum-effect log drops were as follows: for B. fragilis , −3.2 ± 0.2 logs; for C. perfringens , −3.7 ± 0.1 logs; and for GPAC, −2.5 ± 0.1 logs. Although the anaerobes were not eradicated, there was no emergence of resistance. Comparison of the ABE of moxifloxacin to that of ertapenem against B. fragilis indicated that moxifloxacin was superior at 24 h and 48 h. In contrast, ertapenem was superior to moxifloxacin against GPAC at 24 h and 48 h and against C. perfringens at 48 h. Both drugs performed equivalently against C. perfringens at 24 h. Monte Carlo simulations using human serum AUC data and an AUC/MIC anaerobe target of 7.5 suggests a >90% target achievement at MICs of B. fragilis wild-type MIC distribution. The pharmacodynamic properties of moxifloxacin against anaerobes are different than those against aerobic species. The clinical implications of these differences need further exploration.Keywords
This publication has 21 references indexed in Scilit:
- Antimicrobial pharmacodynamics: critical interactions of 'bug and drug'Nature Reviews Microbiology, 2004
- Effect of moxifloxacin versus imipenem/cilastatin treatment on the mortality of mice infected intravenously with different strains of Bacteroides fragilis and Escherichia coliJournal of Antimicrobial Chemotherapy, 2004
- Activities of Moxifloxacin against, and Emergence of Resistance in, Streptococcus pneumoniae and Pseudomonas aeruginosa in an In Vitro Pharmacokinetic ModelAntimicrobial Agents and Chemotherapy, 2003
- Comparative Pharmacodynamics of Three Newer Fluoroquinolones versus Six Strains of Staphylococci in an In Vitro Model under Aerobic and Anaerobic ConditionsAntimicrobial Agents and Chemotherapy, 2002
- Fluoroquinolone Resistance in Anaerobic Bacteria following Exposure to Levofloxacin, Trovafloxacin, and Sparfloxacin in an In Vitro Pharmacodynamic ModelAntimicrobial Agents and Chemotherapy, 2001
- In Vitro Activities of Ertapenem (MK-0826) against Recent Clinical Bacteria Collected in Europe and AustraliaAntimicrobial Agents and Chemotherapy, 2001
- Trovafloxacin in the treatment of intra-abdominal infections: results of a double-blind, multicenter comparison with imipenem/cilastatinThe American Journal of Surgery, 1998
- Mathematical corrections for bacterial loss in pharmacodynamic in vitro dilution modelsAntimicrobial Agents and Chemotherapy, 1995
- Evaluation of activity of temafloxacin against Bacteroides fragilis by an in vitro pharmacodynamic systemAntimicrobial Agents and Chemotherapy, 1993
- In-vitro susceptibility and in-vivo efficacy of antimicrobials in the treatment of intraabdominal sepsis in miceJournal of Antimicrobial Chemotherapy, 1993